AngioDynamics, Inc. Provides Earnings Guidance for the Fiscal Year 2025
July 16, 2024 at 07:23 am
Share
AngioDynamics, Inc. provides earnings guidance for the fiscal year 2025. For the year, the company expects Net sales to be in the range of $282 to $288 million, representing growth of between 4.2% ? 6.4% over fiscal 2024 pro forma revenue of $270.7 million.
AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
ANGIODYNAMICS, INC. 
